Skip to Content

Generic Edarbi Availability

Edarbi is a brand name of azilsartan medoxomil, approved by the FDA in the following formulation(s):

EDARBI (azilsartan kamedoxomil - tablet;oral)

  • Manufacturer: ARBOR PHARMS LLC
    Approval date: February 25, 2011
    Strength(s): EQ 40MG MEDOXOMIL, EQ 80MG MEDOXOMIL [RLD]

Has a generic version of Edarbi been approved?

No. There is currently no therapeutically equivalent version of Edarbi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Edarbi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Benzimidazole derivative and use thereof
    Patent 7,157,584
    Issued: January 2, 2007
    Inventor(s): Kuroita; Takanobu & Sakamoto; Hiroki & Ojima; Mami
    Assignee(s): Takeda Pharmaceutical Company Limited
    The present invention relates to a compound represented by the formula (I) wherein R1 is a group represented by the formula wherein R2, R3, R4, R5, R6, R7 and R8 are each independently a hydrogen atom or a C1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.
    Patent expiration dates:
    • May 22, 2025
      ✓ 
      Drug substance
  • Benzimidazole derivative and use as a II receptor antagonist
    Patent 7,572,920
    Issued: August 11, 2009
    Inventor(s): Kuroita; Takanobu & Sakamoto; Hiroki & Ojima; Mami
    Assignee(s): Takeda Pharmaceutical Company Limited
    The present invention relates to a compound represented by the formula (I) wherein R1 is a group represented by the formula wherein R2, R3, R4, R5, R6, R7 and R8 are each independently a hydrogen atom or a C1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.
    Patent expiration dates:
    • January 7, 2025
      ✓ 
      Patent use: TREATMENT OF HYPERTENSION
      ✓ 
      Drug product
  • Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
    Patent 9,066,936
    Issued: June 30, 2015
    Assignee(s): Takeda Pharmaceutical Company Limited
    The present invention provides a solid pharmaceutical composition containing compound (I) having an angiotensin II receptor antagonistic action and defined in the specification and a pH control agent, which composition is superior in the stability and dissolution property of compound (I).
    Patent expiration dates:
    • March 26, 2028
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 25, 2016 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide